HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.

AbstractPURPOSE:
To investigate the effect of intravitreal bevacizumab on the visual and anatomic outcome of patients with exudative age-related macular degeneration presenting with good visual acuity (VA).
METHODS:
A file review was performed for all consecutive patients with newly diagnosed exudative age-related macular degeneration and initial VA of ≥ 20/40 treated in 2005 to 2010 and followed for at least 6 months. Treatment consisted of 3 loading doses of intravitreal bevacizumab every 6 weeks and was repeated when fluid or hemorrhage was present.
RESULTS:
The cohort included 130 patients (150 eyes). Mean follow-up was 20.2 ± 13.2 months, and mean number of injections was 11.3 ± 6.2. At the last examination, VA was stable or improved in 106 eyes (70.7%); 11 eyes (7.3%) lost ≥ 3 lines. Mean logarithm of the minimum angle of resolution VA measured 0.22 ± 0.1 (0-0.3) at presentation and 0.22 ± 0.2 (0-1.3) at the last visit. Corresponding values for central macular thickness were 267 ± 75 μm (137-562) and 226 ± 75 μm (75-568) (P = 0.14). The most frequent complication (18 eyes, 12%) was corneal epithelial defects.
CONCLUSION:
Prompt intravitreal bevacizumab treatment for newly diagnosed exudative age-related macular degeneration in patients with good initial best-corrected visual acuity is associated with sustained or improved vision and a good safety profile. Attempts should be made to expedite the access of these patients to treatment, regardless of initial VA.
AuthorsRuth Axer-Siegel, Elite Bor, Dan H Bourla, Dov Weinberger, Karin Mimouni
JournalRetina (Philadelphia, Pa.) (Retina) Vol. 32 Issue 9 Pg. 1811-20 (Oct 2012) ISSN: 1539-2864 [Electronic] United States
PMID22825407 (Publication Type: Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
Topics
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors (administration & dosage, adverse effects)
  • Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
  • Bevacizumab
  • Exudates and Transudates
  • Female
  • Follow-Up Studies
  • Humans
  • Intraocular Pressure (drug effects)
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Retina (pathology)
  • Retreatment
  • Retrospective Studies
  • Tonometry, Ocular
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (physiology)
  • Wet Macular Degeneration (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: